Wu J, Balu S, Birk Larsen N, Pulleyblank R, Strømkjær L, Quah A, Wiseman M. Cost-per-Responder Analysis of Tralokinumab versus Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis in the US and Canada. J of Skin [Internet]. 2024 Jan. 16 [cited 2024 Jul. 3];8(1):s317. Available from: https://jofskin.org/33014/index.php/skin/article/view/2397